Related Experiment Video
Updated: Jul 14, 2026

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by
Silvia Galardi1, Neri Mercatelli, Ezio Giorda
1Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier, 1 00133 Rome, Italy.
Abstract:
MicroRNAs are short regulatory RNAs that negatively modulate protein expression at a post-transcriptional level and are deeply involved in the pathogenesis of several types of cancers. Here we show that miR-221 and miR-222, encoded in tandem on chromosome X, are overexpressed in the PC3 cellular model of aggressive prostate carcinoma, as compared with LNCaP and 22Rv1 cell line models of slowly growing carcinomas. In all cell lines tested, we show an inverse relationship between the expression of miR-221 and miR-222 and the cell cycle inhibitor p27(Kip1). We recognize two target sites for the microRNAs in the 3' untranslated region of p27 mRNA, and we show that miR-221/222 ectopic overexpression directly results in p27 down-regulation in LNCaP cells. In those cells, we demonstrate that the ectopic overexpression of miR-221/222 strongly affects their growth potential by inducing a G(1) to S shift in the cell cycle and is sufficient to induce a powerful enhancement of their colony-forming potential in soft agar. Consistently, miR-221 and miR-222 knock-down through antisense LNA oligonucleotides increases p27(Kip1) in PC3 cells and strongly reduces their clonogenicity in vitro. Our results suggest that miR-221/222 can be regarded as a new family of oncogenes, directly targeting the tumor suppressor p27(Kip1), and that their overexpression might be one of the factors contributing to the oncogenesis and progression of prostate carcinoma through p27(Kip1) down-regulation.
Insights
MicroRNAs miR-221 and miR-222 are overexpressed in aggressive prostate cancer, driving tumor growth by down-regulating the p27(Kip1) tumor suppressor. This suggests they act as oncogenes in prostate carcinoma progression.
Area of Science:
- Molecular Biology
- Oncology
- RNA Biology
Background:
- MicroRNAs (miRNAs) regulate gene expression post-transcriptionally and are implicated in cancer pathogenesis.
- Prostate carcinoma exhibits varying growth rates, with aggressive forms potentially linked to specific miRNA profiles.
Purpose of the Study:
- To investigate the role of miR-221 and miR-222 in prostate carcinoma progression.
- To identify the molecular targets and functional consequences of miR-221/222 overexpression in prostate cancer cells.
Main Methods:
- Comparative analysis of miR-221/222 expression in prostate cancer cell lines with different growth rates.
- Luciferase assays to validate p27(Kip1) as a direct target of miR-221/222.
- Cell cycle analysis and soft agar colony formation assays to assess functional impact.
- Antisense locked nucleic acid (LNA) oligonucleotides for miRNA knock-down experiments.
Main Results:
- miR-221 and miR-222 were overexpressed in aggressive PC3 prostate cancer cells compared to slower-growing LNCaP and 22Rv1 cells.
- A direct inverse correlation was observed between miR-221/222 levels and the cell cycle inhibitor p27(Kip1).
- Ectopic miR-221/222 overexpression in LNCaP cells led to p27(Kip1) down-regulation, cell cycle progression (G1 to S shift), and enhanced colony formation.
- Knock-down of miR-221/222 in PC3 cells increased p27(Kip1) levels and reduced clonogenicity.
Conclusions:
- miR-221 and miR-222 function as oncogenes in prostate carcinoma by directly targeting the tumor suppressor p27(Kip1).
- Overexpression of miR-221/222 contributes to prostate cancer oncogenesis and progression via p27(Kip1) down-regulation.
- These miRNAs represent potential therapeutic targets for prostate cancer treatment.
Related Concept Videos
Abnormal Proliferation
MicroRNAs
MicroRNAs
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
